Clinical Trials Logo
  1. Home
  2. Systemic Scleroderma
  3. NCT05726630

Clinical Study of Divozilimab in Patients With Systemic Scleroderma — LIBERIUS  

Systemic Scleroderma Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Divozilimab in Patients With Systemic Scleroderma

Clinical Trial Summary

The study is a randomized, double-blind, placebo-controlled clinical study of the efficacy and safety of divozilimab in patients with systemic scleroderma.The study will enroll adult patients of both sexes diagnosed with active systemic scleroderma according to the ACR/EULAR 2013 criteria with a modified Rodnan skin score (mRSS) of 10 to 20. In patients having signs of ILD, the Forced Vital Capacity (FVC) should be at least 40 % of the due value. Subjects will be randomized to divozilimab or placebo group.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05726630
Study type Interventional
Source Biocad
Contact
Status Recruiting
Phase Phase 3
Start date December 26, 2022
Completion date February 1, 2025
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03629002 - BIOLOGICAL EXPLORATION OF THE VASCULAR FRACTION FROM THE ADIPOSE TISSUE OF PATIENTS WITH SCLERODERMIA
Terminated NCT00377455 - Placebo Controlled Trial of Bosentan in Scleroderma Patients Phase 2
Completed NCT00278525 - Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma Phase 2
Completed NCT00318188 - Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis N/A
Completed NCT03575156 - Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis N/A
Active, not recruiting NCT01413100 - Scleroderma Treatment With Autologous Transplant (STAT) Study Phase 2
Completed NCT00622895 - Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis Phase 1/Phase 2
Active, not recruiting NCT03816189 - Role of Eosinophil in Fibrogenesis of Systemic Sclerosis
Completed NCT01295736 - Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Phase 3
Completed NCT02213705 - Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells Phase 1/Phase 2
Recruiting NCT03508375 - Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis N/A
Active, not recruiting NCT01309997 - Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease Phase 2
Completed NCT00697736 - Cardiac Repercussion of Systemic Sclerodermias N/A
Completed NCT02349009 - Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial Phase 1/Phase 2
Completed NCT00318175 - Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis Phase 2
Completed NCT03262922 - Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment
Recruiting NCT03816345 - Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Phase 1
Recruiting NCT04380831 - TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis Early Phase 1
Terminated NCT00628797 - Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis Phase 1/Phase 2
Recruiting NCT05672992 - Longitudinal Spatial Frequency Domain Imaging Study N/A